TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00640575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone and lidocaine hydrochloride
Description: Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
Study: NCT04022109

Intervention type: DEVICE
Intervention: Breath sampling for VOC detection
Description: Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
Study: NCT04413201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib followed by ICT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib followed by ICT
Study: NCT02058329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Visit
Description: A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
Study: NCT04233996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam 4 g-0.5 g
Description: Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam 4 g-0.5 g
Description: Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
Study: NCT01218048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-surgical radiation
Description: Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin
Description: Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
Study: NCT04553809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENB
Description: ENB for biopsy sampling of peripheral lung lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENB in combination with rEBUS
Description: The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
Study: NCT03262714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
Study: NCT04604717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: 8 weeks of exercise training (twice weekly) of education and exercise
Study: NCT04813965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information about potential chemotherapy-related cognitive symptoms without self-affirmation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information about potential chemotherapy-related cognitive symptoms with self-affirmation
Study: NCT02319707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin in 100 ml NaCl 0.9%
Description: The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
Study: NCT00996164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study: NCT03602859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab (TSR-042)
Description: Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
Study: NCT03602859

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dostarlimab-Placebo
Description: Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
Study: NCT00996164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study: NCT01962402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Description: Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dietary counseling
Description: All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
Study: NCT02183402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study: NCT01984216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y for the gastrojejunostomy reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Billroth II for the gastrojejunostomy reconstruction
Study: NCT02953756

Intervention type: RADIATION
Intervention: Gamma Knife radiosurgery
Description: Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
Study: NCT04022109

Intervention type: DEVICE
Intervention: Breath sampling for VOC detection
Description: Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy

Intervention type: PROCEDURE
Intervention: Surgery material collection for VOC headspace analysis
Description: Only for gastric cancer patients undergoing surgery (Group 1)

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
Study: NCT03602859

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dostarlimab-Placebo
Description: Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
Study: NCT04022109

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota testing
Description: Faecal and gastric contents and biopsy samples for microbiota testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota testing
Description: Faecal and gastric contents and biopsy samples for microbiota testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota testing
Description: Faecal and gastric contents and biopsy samples for microbiota testing
Study: NCT06226623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut
Description: Participants in the intervention group, unlike participants in the control group, were asked to consume 50 g of fresh coconut daily for four weeks.
Study: NCT03316170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support
Description: A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
Study: NCT04233996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 2000 mg
Description: Patients with FN who required empirical treatment with cefepime 2g/8h
Study: NCT04022109

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota testing
Description: Faecal and gastric contents and biopsy samples for microbiota testing
Study: NCT04233996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime 2000 mg
Description: Patients with FN who required empirical treatment with cefepime 2g/8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 1000 mg
Description: Patients with FN who required empirical treatment with meropenem 1g/8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem 1000 mg
Description: Patients with FN who required empirical treatment with meropenem 1g/8h
Study: NCT03740581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Basal Bolus regimen (Participant to receive, Insulin \>= 3 times per day)
Study: NCT02176265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Qvanteq bioactive coronary stent
Description: PCI
Study: NCT03936803

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic interval training exercise .
Description: Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electro acupuncture
Description: electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks
Study: NCT03005665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT00226291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synthesized evidence report
Description: Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
Study: NCT03316170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT Sampling
Description: A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail.
Study: NCT01412333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab-matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a-matching placebo
Study: NCT00638651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm Nd:YAG laser
Description: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
Study: NCT00074828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY517717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Study: NCT00638651

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 1064 nm Nd:YAG laser
Description: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
Study: NCT04521127

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 \* 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
Study: NCT00625872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Somatropin
Description: Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
Study: NCT02588495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food intake
Description: Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
Study: NCT01080560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Capsules USP (Modified) 100 mg
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Capsules USP (Modified) 100 mg
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
Study: NCT01157988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibritumomab tiuxetan (Zevalin)
Description: During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
Study: NCT02532309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5mg，10mg，20mg)
Description: Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Description: Rosuvastatin 5mg/day
Study: NCT05344131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)
Description: Biopsychosocial approach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)
Description: Biopsychosocial approach
Study: NCT04513366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212 low-dose
Description: IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
Study: NCT00368602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timoptic
Description: Timoptic to be applied to the target wound daily for up to 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
Study: NCT00321971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PST-MCI/AD Caregiving
Description: The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NT-MCI/AD Caregiving
Description: The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
Study: NCT01164176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis